News

Medexprim engaged in the EU CHAIMELEON project

Medexprim is very proud to start its new collaboration in the H2020 EU CHAIMELEON project.

CHAIMELEON aims to set up a structured repository for health imaging data to be openly reused in AI experimentation for cancer management. By 2024, an EU-wide repository will be built as a distributed infrastructure in full compliance with legal and ethics regulations in the involved countries.

Clinical partners and external collaborators will populate the Repository with multimodality (MR, CT, PET/CT) imaging and related clinical data for historic and newly diagnosed breast, lung, prostate and colorectal cancer patients.

Medexprim is involved in two complementary ways:

  • First as a contributor to the winning consortium. Medexprim’ roles cover legal, interoperability, platform architecture and internal consulting for data integration.

  • Then through Karine Seymour’s key role in the project as the designated technical coordinator of the consortium: « I am very proud and excited to take part to this ambitious EU project, says Karine. It follows the Primage project in which we were already involved. It’s a big challenge, but it’s 100% in line with Medexprim’s core mission and expertise. We were waiting for such a program to get recognition from our peers and to establish our notoriety. Now, we have to deliver ! »

 

The first milestone will be on October 2021 with the first clinical datasets made available. More information

This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 952172.


Read More

2 Releases in September and a Major Version upcoming in December !

Medexprim Suite™ is now bigger and better than ever before, with the simultaneous release of Radiomics Enabler® Version 1.4 and 1.5.
Under the hood, these two versions have exactly the same functionality.
Aditionally, v.1.5 updates Medexprim Suite™ to run on Docker, which makes installation and upgrade much easier. This new version can run on any operating system that supports Docker, including Windows 10.

Both versions include several important new features that our customers asked for:

  • an Audit Trail to record user logins and access to data.
  • an integrated Dicom Viewer to help validate correct de-identification of extracted Dicom images and Dicom SR files, prior to releasing data to a research project.
  • a significantly improved workflow making it possible to investigate and fix extraction errors, without viewing patient data and view the progress of a batch through the various processing stages. In particular, this allows Medexprim to effectively extend its support to client’s projects, in full respect of the regulations.
  • a clearer display of batch processing status, to show when a batch has completed de-identification and whether any files have been quarantined.
  • an extended API so that all batch related search, selection and extraction functions can be launched by external applications.

Version 2.0 is scheduled. It will feature an updated GUI and improvements to pipeline management. It will also be integrated with our new Indexa™ product, indexing the entire local PACS & RIS data in real time, aimed at accelerating searches & queries. More information here

Read More

European Commission’s Seal of Excellence

This summer, Medexprim received the European Commission’s Seal of Excellence for MIDAC (Medical Imaging Data Against Coronavirus), our project submitted to the EIC Accelerator COVID call. MIDAC’s goal was to constitute a centralized, collaborative and openly accessible Datalake of imaging exams and ancillary data with patients affected or not by Covid-19, and either release them to a qualified party for research, or help constitute synthetic control arms for existing clinical trials. This reinforces Medexprim’s position as a leader in the market of complex dataset creation & sourcing for clinical research, and encourages us to apply to the next “EIC Accelerator” call in October 2020, with a more ambitious project.

Together with leading EU university hospitals, with MIDAC, Medexprim’s mission was to facilitate the creation and enhancement of medical imaging databases and contextual data for research and for the development of new applications based on artificial intelligence.

Leveraging on this achievement, the Medexprim team is now applying the same approach to treatment against cancer and rare diseases. A great opportunity for our international partners to join our development dynamic !

Read More

Join us !

Medexprim is hiring it Responsable Marketing & Partnerships Manager. If you wish to contribute to the progress of medicine and to evolve in a rich multidisciplinary environment, join us! Please see job description here.

Apply to hr@medexprim.com.

Read More
logo medexprim

Replay of the webinar ” “Bridging global COVID-19 RWE initiatives between care providers and pharma”

In this webinar Medexprim and Graticule convened a panel of experts that bridge across geographies and backgrounds to discuss solutions for sharing advanced Real World Data for COVID-19 research. The panel shares their expertise on data needs, data sharing, and their vision for success.

You can find the replay of the webinar here, and the written transcript here.

If you are interested for further related events, please fill your contact information in the contact form.

Read More
logo medexprim

Webinar “Bridging global COVID-19 RWE initiatives between care providers and pharma”

Medexprim is very pleased and proud to announce a joint Medexprim /Graticule on Tuesday 28 April @ 6PM CET, 12PM EST “Bridging global COVID-19 RWE initiatives between care providers and pharma”.

The goal is to spark a worthy discussion on the gap between COVID19 existing RWE, and the ideal datasets for use in clinical research, and unleash bridging ideas.

Register at https://lnkd.in/g7cRW4v

 

Read More

Romain Cazavan becomes President of Medexprim

Karine Seymour, founder of Medexprim, hands over the Presidency of the company to Romain Cazavan. She continues to manage the Operations Department and the product management.

Medexprim, a hyper-growth company specialized in “big data” in medical imaging, announces a reorganization of its leadership team. The new organization will enable to balance responsibilities and provide greater agility to respond to the challenges and opportunities ahead. The objective is to triple its workforce and increase sales tenfold within 3 years.

Thus, the General Assembly of Medexprim of April 9, 2020 appointed Romain Cazavan, President of the Company. Karine Seymour, the founder, remains a corporate officer and continues to manage the product roadmap and customer projects.

Read More

Graticule and Medexprim announce their partnership to support global Real World Evidence (RWE) initiatives, federating US + EU radiology technology and data networks

Boston, Mass – US-based Graticule and France based Medexprim announced a partnership today to provide a federated global network to power complex RWE (Real World Evidence) studies. The two companies have established complementary infrastructure and relationships with health systems and health technology vendors to support research on deidentified radiology data combined with longitudinal health records. Jointly Graticule and Medexprim provide Life Sciences and AI technology clients with a global solution to advance medical research and development across multiple types of projects including HEOR (Health Economics and Outcomes Research), epidemiology, biomarker discovery, feasibility studies, clinical trial recruitment, and AI powered diagnostics.

Imaging data offers significant analytics opportunities beyond traditional deidentified administrative data. Medical imaging provides a wealth of unmined information because radiologists can only directly review a small fraction of the detailed series of images. Many patients struggle with undiagnosed disorders navigating diagnostic odysseys for years before their physicians determine they have a specific treatable disease. Building machine learning models from radiology data on cases and controls allows uninterpreted details from images and radiology reports to be automatically detected and scored for new uses. These models can be translated into practice to scan real time and historical imaging studies to provide benefits such as identifying cases eligible for clinical trials, to prompt follow-up to prescribe appropriate medications to patients, and to quantitatively track how diseases are progressing during treatment.

To make new tools available for use in clinical decision making requires development and regulatory validation in a variety of settings, imaging platforms, and care delivery models. This complexity is compounded when datasets are needed on a global scale, which is increasingly a requirement. For example when RWE datasets are used to gain regional regulatory market access approvals. This complexity is the foundation for the Graticule and Medexprim alliance.

The two companies have worked in US and EU to secure rights to access and use targeted datasets with processes that respect region-specific data privacy rules including implementing processes to handle local consent and data sovereignty regulations. The companies have combined software packages and engineering expertise to establish a portfolio of technologies including NLP, data enrichment technologies, de-identification, encryption, and traceability to enrich health system sites participating in sponsored research.

Medexprim will be featuring the partnership solutions at the Radiological Society of North America’s annual congress (RSNA 2019) in Chicago, Ill, December 1st – December 5th at their booth 11313B — located in the AI Showcase – Level 2, close to the AI theater.

Graticule provides advisory services to life sciences clients seeking to design and source data for advanced RWE projects. Graticule has established the Graticule Research Network through relationships with US health systems seeking to participate in sponsored research studies that leverage imaging data. Graticule produces a data subscription product, GLIMPS (Graticule Life Image Machine Processed Set), which offers a directory to identify radiology studies available for extraction as raw image sets for analytical projects.

Medexprim Suite™ is an interoperable software platform which provides dedicated tools for advanced patients selection, automatic extraction, specific pseudonymization/ de-identification, enrichment, validation, tracing and secured routing of larges datasets (DICOM images + related contextual data & reports).

“With the exponential growth of imaging biomarkers and machine learning in radiology, we want to be able to provide our life sciences customers with a global solution as soon as possible” says Dan Poscover, CEO of Graticule. “Medexprim’s growing worldwide installed base, historic EU presence, and tools in the Medexprim Suite™ accelerate our solution roadmap by 3 years.”

“Graticule’s expertise and relationships with large pharma R&D processes and teams constitute a very tangible accelerator to our data brokerage activities. With this partnership, we will expand from our traditional Artificial Intelligence projects in medical imaging, to pharma and medtech projects,” says Karine Seymour, Medexprim CEO. “We look forward to enhancing Graticule’s capabilities to onboard US health systems, by deploying our Medexprim Suite™.” adds Nicolas Dubost, CSO.

The combined offering from Graticule and Medexprim allows Life Sciences researchers to swiftly access RWE datasets constituted from a variety of global sources (EU, US) and systems (Existing private or public datasets, as well as new RWE datasets extracted from PACS, EMR, RIS, LIS), extract corresponding reports and imaging exams, curate and pseudonymize the results. The cleansed contextualized data can then be accessed by data scientists and other researchers interested in finding correlations between imaging features and other phenotypes and/or genotypes, as well as developing training data sets for machine learning algorithms.

About Graticule 

Graticule provides data subscriptions and on-demand data collaborations to pharma clients to unlock the value in advanced real world data such as imaging, genomics, and free text notes. Graticule provides extensions to technologies with mature adoption within health systems to eliminate IT overhead and to accelerate the data collaboration process. Graticule is focused on curating data resources and applications for Neurology, Cardiology, Oncology and Rare Diseases. Uses of Graticule data by life sciences clients include machine learning model development, biomarker development, clinical trial recruitment, and identification of undiagnosed patients.  For more information, visit Graticule at www.graticule.life.

About Medexprim

Medexprim (www.medexprim.com) is a software editor and integrator, and provides IT and Consulting Solutions & Services.   With a growing global installed base, Medexprim supports healthcare providers in the efficient and secure exploitation of their imaging exams and associated data, for research and big data projects. Medexprim helps them leveraging these resources in external collaborations, with a tailored contractual and technical framework, fostering collaboration between healthcare providers and life sciences clients.

Press release in PDF

Contact press :

Graticule Dan Poscover, CEO 617-899-2866 dposcover@graticule.life
  Dan Housman, CTO 617-216-9921 dhousman@graticule.life
Medexprim Karine Seymour, CEO + 33 531 615 970 kseymour@medexprim.com
  Nicolas Dubost, CCO +33 680 317 341 ndubost@medexprim.com
Read More